Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 256-259, 2013.
Artículo
en Inglés
| WPRIM
| ID: wpr-194718
ABSTRACT
Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neumonía
/
Recurrencia
/
Proteínas Tirosina Quinasas
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Estudios de Seguimiento
/
Corticoesteroides
/
Enfermedades Pulmonares Intersticiales
/
Mesilatos
/
Tumores del Estroma Gastrointestinal
/
Mesilato de Imatinib
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Tuberculosis and Respiratory Diseases
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS